Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Evans Blue Free Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 6/20 | 0.77 |
| ▸ | ENPP2 | Q13822 | 3/20 | 1.00 |
| ▸ | HSPD1 | P10809 | 2/20 | 1.00 |
| ▸ | HSPE1 | P61604 | 2/20 | 1.00 |
| ▸ | TST | Q16762 | 2/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 2/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.77 |
| ▸ | RECQL | P46063 | 5/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.77 |
| ▸ | HPGD | P15428 | 4/20 | 0.77 |
| ▸ | MEN1 | O00255 | 4/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.77 |
| ▸ | APEX1 | P27695 | 2/20 | 0.77 |
| ▸ | USP2 | O75604 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Evans Blue Free Acid SCHEMBL103701 | 1.00 | ENPP2 (1.00) | ENPP2HSPD1HSPE1TSTPTPN1 | |
| Evans Blue Free Acid SCHEMBL29377040 | 1.00 | ENPP2 (1.00) | ENPP2HSPD1HSPE1TSTPTPN1 | |
| Evans Blue Free Acid SCHEMBL30392230 | 1.00 | ENPP2 (1.00) | ENPP2HSPD1HSPE1TSTPTPN1 | |
| Evans Blue Free Acid SCHEMBL29601874 | 1.00 | ENPP2 (1.00) | ENPP2HSPD1HSPE1TSTPTPN1 | |
| Evans Blue Free Acid SCHEMBL29381789 | 1.00 | ENPP2 (1.00) | ENPP2HSPD1HSPE1TSTPTPN1 | |
| Evans Blue Free Acid SCHEMBL29609615 | 0.87 | MEN1 (0.98) | ENPP2HSPD1HSPE1TSTPTPN1 | |
| Chicago Sky Blue SCHEMBL93506 | 0.87 | THRB (1.00) | ENPP2HSPD1HSPE1TSTPTPN1 | |
| Chicago Sky Blue SCHEMBL29358365 | 0.87 | THRB (1.00) | ENPP2HSPD1HSPE1TSTPTPN1 | |
| Chicago Sky Blue SCHEMBL29401288 | 0.87 | THRB (1.00) | ENPP2HSPD1HSPE1TSTPTPN1 | |
| Chicago Sky Blue SCHEMBL30201536 | 0.87 | THRB (1.00) | ENPP2HSPD1HSPE1TSTPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4426280-B1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA ALEXANDRE (CH) | 2026-03-18 | — | — | EP | disclosed |
| US-20250057791-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA ALEXANDRE (CH) | 2025-02-20 | — | — | US | disclosed |
| WO-2023111938-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA, Alexandre (CH) | 2023-06-22 | — | — | WO | disclosed |
| WO-2011109650-A1 | METHOD OF TREATING ACUTE LUNG INJURY USING SPHINGOSINE 1 PHOSPHATE ANALOGES OR SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONISTS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-09-09 | — | — | WO | disclosed |
| US-7122572-B2 | For use in Hydrogen Bonding Liquid Chromatography, environmental remediation by removal of undesired ions or neutral molecules, removal of phosphate for kidney dialysis, drug delivery, separation | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2006-10-17 | — | — | US | disclosed |
| US-7041819-B2 | Halogenated calixpyrroles and uses thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-05-09 | — | — | US | disclosed |
| US-6984734-B2 | Cyclo[n]pyrroles and methods thereto | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-01-10 | — | — | US | disclosed |
| US-20030229131-A1 | Cyclo[n]pyrroles and methods thereto | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-12-11 | — | — | US | disclosed |
| WO-2003018548-A2 | HALOGENATED CALIXPYRROLES, CALIXPYRIDINOPYRROLES AND CALIXPYRIDINES, AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2003-03-06 | — | — | WO | disclosed |
| US-20020115566-A1 | Halogenated calixpyrroles, calixpyridinopyrroles and calixpyridines, and uses thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2002-08-22 | — | — | US | disclosed |
| US-20020026047-A1 | Calixpyrroles, calixpyridinopyrroles, and calixpyridines | BOARD OF REGENTS, THE | 2002-02-28 | — | — | US | disclosed |
| US-6262257-B1 | SELECTIVE ION- AND NEUTRAL MOLECULE-BINDING AGENTS FORMING SUPRAMOLECULAR ENSEMBLES, AND ION- AND NEUTRAL MOLECULE-SEPARATION AGENTS | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229131-A1 | Cyclo[n]pyrroles and methods thereto | PPOX, QPCT, PPIE | THRB 4833/4885ENPP2 2037/4885HSPD1 3048/4885 |
| US-20020115566-A1 | Halogenated calixpyrroles, calixpyridinopyrroles and calixpyridines, and uses thereof | CALD1, CALU, CLASP1 | THRB 2317/4885ENPP2 4682/4885HSPD1 510/4885 |
| US-20020026047-A1 | Calixpyrroles, calixpyridinopyrroles, and calixpyridines | CALD1, DAP3, CALR | THRB 4320/4885ENPP2 3271/4885HSPD1 1131/4885 |
| US-20250057791-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | P2RX2, P2RX3, P2RX1 | THRB 1531/4885ENPP2 41/4885HSPD1 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.